Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 320

stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft
injury in a rat renal allograft model. J Am Soc Nephrol 2003;14:214-25.
[291] Herrero-Fresneda I, Torras J, Franquesa M, Vidal A, Cruzado JM, Lloberas N, et al.
HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic
inflammatory-induced mechanisms. Kidney Int 2006;70:265-74.
[292] Beutler E. Gaucher disease as a paradigm of current issues regarding single gene muta-
tions of humans. Proc Natl Acad Sci USA 1993;90:5384-90.
[293] Neufeld EF. Lysosomal storage diseases. Ann Rev Biochem 1991;60:257-80.
[294] Futerman AH, Van Meer G. The cell biology of lysosomal storage disorders. Nat Rev
Mol Cell Biol 2004;5:554-65.
[295] Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern
management. Br J Hematol 2005;129:178-88.
[296] Kornfeld S, Mellman I. The biogenesis of lysosomes. Ann Rev Cell Biol
1989;5:483-525.
[297] Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to
intravenous infusion of glucocerebrosidase in a patient with Gaucher disease. Proc Natl
Acad Sci USA 1990;87:1913-16.
[298] Cox T, Lachmann R, Hollak C, Aerts J, Van Weely S, Hrebicek M, et al. Novel oral
treatment of Gaucher disease with N-butyldeoxynojirimycin (OGT 918) to decrease
substrate biosynthesis. Lancet 2000;355:1481-5.
[299] Sorge J, Kuhl W, West C, Beutler E. Complete correction of the enzymatic defect of
type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc Natl Acad
Sci USA 1987;84:906-9.
[300] Liu CM, Dunigan JT, Watkins SC, Bahnson AB, Barranger JA. Long-term expression,
systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in
mice transplanted with genetically modified primary myoblasts. Hum Gene Ther 1998;
9:2375-84.
[301] Hong YB, Kim EY, Yoo HW, Jung SC. Feasibility of gene therapy in Gaucher disease
using an adeno-associated virus vector. J Hum Genet 2004;49:536-43.
[302] Krall WJ, Challita PM, Perlmutter LS, Skelton DC, Kohn DB. Cells expressing human
glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous
system microglia after murine bone-marrow transplantation. Blood 1994;83:2737-48.
[303] Schiffmann R, Medin JA, Ward JM, Stahl S, Cottlerfox M, Karlsson S. Transfer of the
human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipi-
ents- successful engraft engraftment and long-term expression of the transgene. Blood
1995;86:1218-27.
[304] Kim EY, Hong YB, Lai ZN, Cho YH, Brady RO, Jung SC. Long-term expression of the
human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived
cells transformed with a lentivirus vector. J Gene Med 2005;7:878-87.
[305] McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, et al.
AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in
the visceral organs of a mouse model of Gaucher disease. J Gene Med 2006;8:719-29.
[306] Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, Ehinger M, et al. Effective
cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA
2006;103:13819-24.
[307] Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, et al. Retroviral
transfer of the glucocerebrosidase gene into CD34 cells from patients with Gaucher
disease: In vivo detection of transduced cells without myeloablation. Hum Gene Ther
1998;9:2629-40.